ESMO 2021 Congress: CRC highlights
Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada CRC is the third most common cancer in Quebec, with projected cases in 2020 consisting of 3900 in males, and 3100 in females. During the first wave of the COVID-19 pandemic which extended from March to July 2020, Quebec experien...
CONTINUE READING
Antibiotic use and colon cancer: more evidence of link
A Swedish population study published this month in the Journal of the National Cancer Institute adds to the body of evidence that shows an association between antibiotic use and an increased risk of developing colon cancer. Evidence from a large Scottish study published earlier this year found that a history of antibiotic us...
CONTINUE READING
Clinical implications of the ongoing GALAXY trial
Adjuvant (post-surgical) chemotherapy is useful in reducing the risk of disease recurrence and improving survival in patients who have undergone colorectal cancer (CRC) surgery. The GALAXY trial is evaluating the role for circulating tumour DNA (ctDNA) as a predictive biomarker to select patients with CRC who are most likely...
CONTINUE READING
Developing a better fecal immunochemical test (FIT) for colon cancer screening
The fecal immunochemical test (FIT) is a widely used colorectal cancer (CRC) screening test that uses a specific antibody to detect hemoglobin in the stool - an indication of the presence of blood which can be sign of pre-cancer. FIT can be sent to a person by mail and completed at home, and does not require any type of bowe...
CONTINUE READING
Colon cancer data reinforce need to reduce unnecessary antibiotic use
New findings from a study presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021 (30 June – 3 July) suggest that excessive antibiotic use may increase the risk of colon cancer, particularly among people below the age of 50[1]. The study draws attention to the estimated 65...
CONTINUE READING
